We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 2,822

Keeping your brand exclusive: how a luxury image can disappear
  • Bird & Bird LLP
  • Netherlands, European Union
  • February 14 2019

An exclusive image is the prime asset of any luxury brand. However, a recent case by the Court of Appeal in The Hague, The Netherlands, showed that


Brexit in Germany - Government set to relax dismissal protection for risk takers in significant institutions
  • Freshfields Bruckhaus Deringer
  • Netherlands, United Kingdom, European Union, Germany
  • February 13 2019

In December 2018 the German Government submitted the Draft Bill Supplementing the Act on Tax-Related Provisions Concerning the Withdrawal of the


The Netherlands Commercial Court - Now open for business!
  • Freshfields Bruckhaus Deringer
  • Netherlands, European Union
  • February 12 2019

6 February 2019 marked the grand opening of the Netherlands Commercial Court (NCC). The NCC is a newly founded court within the Dutch judiciary


On the rise of ‘Robin Hood’ pharmacies
  • Kilburn & Strode LLP
  • Netherlands, United Kingdom, European Union
  • February 12 2019

2.6 billion British pound sterling. That is the average cost of bringing a new drug to market. Pharmaceutical companies willing and able to make such


Monogram ‘LV’ kan ook los van het ‘Monogram Canvas’ een bekend merk zijn
  • Novagraaf
  • Netherlands, European Union
  • February 11 2019

Louis Vuitton is een grote naam in de fashionindustrie en brengt vooral tassen, koffers, accessoires en kleding op de markt. Hierbij wordt vrijwel


The ACM follows EU approach in its first pharmaceutical merger
  • Stibbe
  • Netherlands, European Union
  • February 7 2019

The Dutch Authority for Consumers and Markets (ACM) recently reviewed its first merger between two pharmaceutical companies. In its conditional


HealthBit: NZa en Europese Commissie publiceren rapporten over dure geneesmiddelen
  • Loyens & Loeff
  • Netherlands, European Union
  • February 6 2019

Hoge medicijnprijzen zijn momenteel prominent in het nieuws. Afgelopen week publiceerden zowel de Nederlandse Zorgautoriteit (NZa) als de Europese


Data Protection Impact Assessment triggers: Clarity or confusion?
  • PrivacyPerfect
  • Netherlands, European Union, Global
  • February 6 2019

Impact assessments are essentially risk management tools, whether they are concerned with the environment, society, business, or personal data. In


Britse beleggingsondernemingen worden na 30 maart 2019 tijdelijk vrijgesteld van de vergunningplicht in Nederland
  • Stibbe
  • Netherlands, United Kingdom, European Union
  • February 5 2019

De minister van Financiën heeft op 4 februari jl. Een wijziging van de Vrijstellingsregeling Wft gepubliceerd. Ondernemingen die vanuit het Verenigd


Copyright in a Taste - A “Work” in Progress
  • McCann FitzGerald
  • Netherlands, European Union, Global
  • February 5 2019

The CJEU in Levola Hengelo BV v Smilde Foods BV ("Smilde") gave an important judgment on the meaning of a "work" under EU law and whether taste is